NRX Pharmaceuticals IncFRA NRX Stock Report

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB). Its ZYESAMI (aviptadil) is an investigational drug for COVID-19-related respiratory failure. The firm has completed a Phase IIb/III clinical study in patients with acute respiratory failure in COVID-19.